A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury*

Abstract

Fish oil did not reduce biomarkers of pulmonary or systemic inflammation in patients with acute lung injury, and the results do not support the conduct of a larger clinical trial in this population with this agent. This experimental approach is feasible for proof-of-concept studies evaluating new treatments for acute lung injury.